Not provided
Not provided
Not provided
Not provided
Not provided
Funding not approved
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single center, prospective, investigational study to evaluate the safety and efficacy of prostatic artery embolization (PAE) for the treatment of moderate to severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Embolization will be performed with LC Bead LUMI particles using a balloon occlusion microcatheter or standard microcatheter.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Balloon occlusion microcatheter | Experimental | Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter. |
|
| Standard microcatheter | Experimental | Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prostatic artery embolization | Device | Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with treatment related adverse events assessed by CTCAE v4.0. | 12 months post PAE | |
| Mean change from baseline in symptom score using the IPSS scale at 6 months | Baseline and 6 months post PAE |
| Measure | Description | Time Frame |
|---|---|---|
| Mean change from baseline in Qmax (maximum urinary flow) | Baseline, 6 months and 12 months post PAE | |
| Mean change from baseline in PVR (post void residual) | Baseline, 6 months and 12 months post PAE |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew Picel, MD | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94305 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011470 | Prostatic Hyperplasia |
| D059411 | Lower Urinary Tract Symptoms |
| ID | Term |
|---|---|
| D011469 | Prostatic Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Mean change from baseline in prostate volume | Baseline, 6 months and 12 months post PAE |
| Mean change from baseline in IPSS to measure long-terms subjective outcome | Baseline, 12 and 24 months post PAE |
| D052801 |
| Male Urogenital Diseases |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |